J&J jumps into gamma delta field with Lava collaboration; Myokardia guns for $605M raise
→ Jumping into the erupting field of gamma delta T cells, J&J has signed a collaboration with Lava Therapeutics. Like a series of other biotechs that have emerged in recent years, Netherlands-based Lava develops bispecific antibodies that grab gamma delta T cells, which are involved in recognizing cancers and other types of antigens, to attack evasive tumors. Financial terms were not disclosed.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
